Drug Discovery

Karuna Therapeutics and PsychoGenics announce drug discovery collaboration

Karuna Therapeutics announced that the companies have entered a multi-year drug discovery and development agreement to identify potential novel drug candidates for the treatment of severe neuropsychiatric disorders.

Daiichi Sankyo, AstraZeneca sign $6bn worth deal for DS-1062

Daiichi Sankyo has signed a global development and commercialisation deal worth up to $6bn with AstraZeneca for its cancer drug candidate DS-1062.

Moderna announces expansion of BARDA agreement to support larger phase 3 programme for Covid-19 vaccine

Moderna, a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced a modification to its contract with the Biomedical Advanced Research and Development Authority (BARDA) for an additional commitment of up to $472 million to support late stage clinical development including the expanded Phase 3 study of the Company’s mRNA vaccine candidate (mRNA-1273) against Covid-19.

Novartis announces phase III study of Jakavi in chronic graft-versus-host disease met primary and key secondary endpoints

Novartis announced that the Phase III REACH3 study evaluating Jakavi® (ruxolitinib) in patients with steroid-refractory or steroid-dependent chronic graft-versus-host disease (GvHD) met its primary endpoint of superior overall response rate (ORR) at Week 24 versus best available therapy (BAT).

7000RMS Services

Expert system services provide peace of mind and ensure that your analyzer is performing optimally to deliver process control.

Roche, Jnana sign multi-target collaboration deal for small molecule drugs

Jnana Therapeutics has signed a multi-target collaboration and license deal worth over $1bn with Roche for the discovery of small molecule drugs for the treatment of immune-mediated and neurological diseases.

Gilead Sciences to buy 49.9% stake in Tizona Therapeutics for $300m

Gilead Sciences has agreed to invest up to $300m to acquire a 49.9% equity stake in clinical-stage immunotherapy company Tizona Therapeutics.

JW Therapeutics acquires Syracuse and license to Eureka’s solid tumour technology in China

JW Therapeutics announced the acquisition of Syracuse Biopharma (Hong Kong) Limited, which includes the license for Eureka Therapeutics’ ARTEMIS antibody TCR and solid tumor technology for exclusive use in China and the ASEAN countries.

GSK to acquire 10% stake in German biotech company CureVac

British drugmaker GlaxoSmithKline (GSK) has agreed to invest up to €150m to acquire a 10% stake in German biotech company CureVac.